The speed of progression towards obsessive-compulsive disorder.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 03 2020
Historique:
received: 25 06 2019
revised: 17 09 2019
accepted: 09 12 2019
entrez: 15 2 2020
pubmed: 15 2 2020
medline: 16 2 2021
Statut: ppublish

Résumé

There is current interest in the elaboration of early intervention programs for obsessive-compulsive disorder (OCD). To this end, it is important to investigate the speed of progression from subthreshold symptoms to diagnosable OCD. In this study, we have retrospectively investigated the speed of progression towards full-blown OCD and sociodemographic and clinical factors associated with a faster transition. Patients enrolled in the Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders (N = 954) were interviewed with a comprehensive assessment battery that included the interval (in years) between the onset of subthreshold OCD symptoms and the onset of full-blown OCD. It took a median of 7 years (interquartile range: 2-13 years) for subthreshold symptoms to convert to diagnosable OCD. Faster OCD onset was associated with lower age at the time of assessment, male gender, being in new romantic states as precipitants for compulsions, greater severity of sexual/religious symptoms and lower severity of hoarding and YBOCS compulsions severity scores, greater rates of generalized anxiety disorder and agoraphobia without panic disorder, and negative family history for OCD. The retrospective design of this study allowed for susceptibility to memory bias about age at onset of OCD symptoms. We were unable to capture progressions taking less than 12 months. We could identify a specific phenotype that was more likely to escalate rapidly to clinical levels within this large clinical sample. This phenomenon may be particularly relevant in the context of selecting individuals for early intervention initiatives in situations when resources are scarce.

Sections du résumé

BACKGROUND
There is current interest in the elaboration of early intervention programs for obsessive-compulsive disorder (OCD). To this end, it is important to investigate the speed of progression from subthreshold symptoms to diagnosable OCD. In this study, we have retrospectively investigated the speed of progression towards full-blown OCD and sociodemographic and clinical factors associated with a faster transition.
METHODS
Patients enrolled in the Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders (N = 954) were interviewed with a comprehensive assessment battery that included the interval (in years) between the onset of subthreshold OCD symptoms and the onset of full-blown OCD.
RESULTS
It took a median of 7 years (interquartile range: 2-13 years) for subthreshold symptoms to convert to diagnosable OCD. Faster OCD onset was associated with lower age at the time of assessment, male gender, being in new romantic states as precipitants for compulsions, greater severity of sexual/religious symptoms and lower severity of hoarding and YBOCS compulsions severity scores, greater rates of generalized anxiety disorder and agoraphobia without panic disorder, and negative family history for OCD.
LIMITATIONS
The retrospective design of this study allowed for susceptibility to memory bias about age at onset of OCD symptoms. We were unable to capture progressions taking less than 12 months.
CONCLUSIONS
We could identify a specific phenotype that was more likely to escalate rapidly to clinical levels within this large clinical sample. This phenomenon may be particularly relevant in the context of selecting individuals for early intervention initiatives in situations when resources are scarce.

Identifiants

pubmed: 32056748
pii: S0165-0327(19)31659-3
doi: 10.1016/j.jad.2019.12.016
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

181-186

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interests We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Auteurs

Emma M Thompson (EM)

Turner Institute for Brain and Mental Health, Monash University, 770 Blackburn Road, Clayton, Victoria 3168, Australia. Electronic address: emma.thompson2@monash.edu.

Albina R Torres (AR)

Department of Neurology, Psychology and Psychiatry, Botucatu Medical School, Univ Estadual Paulista (UNESP), Brazil.

Lucy Albertella (L)

Turner Institute for Brain and Mental Health, Monash University, 770 Blackburn Road, Clayton, Victoria 3168, Australia. Electronic address: lucy.albertella@monash.edu.

Ygor A Ferrão (YA)

Department of Psychiatry, Federal University of Health Sciences of Porto Alegre (UFCSPA), Brazil.

Jeggan Tiego (J)

Turner Institute for Brain and Mental Health, Monash University, 770 Blackburn Road, Clayton, Victoria 3168, Australia. Electronic address: jeggan.tiego@monash.edu.

Roseli G Shavitt (RG)

Department and Institute of Psychiatry, University of São Paulo (USP), Brazil.

Maria Conceição do Rosario (M)

Department of Psychiatry, Federal University of São Paulo (UNIFESP), Brazil.

Euripedes C Miguel (EC)

Department and Institute of Psychiatry, University of São Paulo (USP), Brazil.

Leonardo F Fontenelle (LF)

Turner Institute for Brain and Mental Health, Monash University, 770 Blackburn Road, Clayton, Victoria 3168, Australia; Obsessive, Compulsive, and Anxiety Spectrum Research Program. Institute of Psychiatry, Federal University of Rio de Janeiro (UFRJ) & D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil. Electronic address: lfontenelle@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH